215 related articles for article (PubMed ID: 18704226)
61. [Polyoxometalates. A new class of inorganic CK2 inhibitors].
Prudent R; Hasenknopf B; Cochet C
Med Sci (Paris); 2008 Dec; 24(12):1012-4. PubMed ID: 19116103
[No Abstract] [Full Text] [Related]
62. Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways.
Piazza F; Manni S; Ruzzene M; Pinna LA; Gurrieri C; Semenzato G
Leukemia; 2012 Jun; 26(6):1174-9. PubMed ID: 22289987
[TBL] [Abstract][Full Text] [Related]
63. Toward the rational design of protein kinase casein kinase-2 inhibitors.
Sarno S; Moro S; Meggio F; Zagotto G; Dal Ben D; Ghisellini P; Battistutta R; Zanotti G; Pinna LA
Pharmacol Ther; 2002; 93(2-3):159-68. PubMed ID: 12191608
[TBL] [Abstract][Full Text] [Related]
64. Dependence of HSP27 cellular level on protein kinase CK2 discloses novel therapeutic strategies.
Borgo C; Vilardell J; Bosello-Travain V; Pinna LA; Venerando A; Salvi M
Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2902-2910. PubMed ID: 30279146
[TBL] [Abstract][Full Text] [Related]
65. Design, synthesis and evaluation of 2-phenylisothiazolidin-3-one-1,1-dioxides as a new class of human protein kinase CK2 inhibitors.
Chekanov MO; Ostrynska OV; Synyugin AR; Bdzhola VG; Yarmoluk SM
J Enzyme Inhib Med Chem; 2014 Jun; 29(3):338-43. PubMed ID: 23578312
[TBL] [Abstract][Full Text] [Related]
66. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors.
Pagano MA; Poletto G; Di Maira G; Cozza G; Ruzzene M; Sarno S; Bain J; Elliott M; Moro S; Zagotto G; Meggio F; Pinna LA
Chembiochem; 2007 Jan; 8(1):129-39. PubMed ID: 17133643
[TBL] [Abstract][Full Text] [Related]
67. Casein kinases as potential therapeutic targets.
Cozza G; Pinna LA
Expert Opin Ther Targets; 2016; 20(3):319-40. PubMed ID: 26565594
[TBL] [Abstract][Full Text] [Related]
68. Inhibition of protein kinase CK2 expression and activity blocks tumor cell growth.
Zhu D; Hensel J; Hilgraf R; Abbasian M; Pornillos O; Deyanat-Yazdi G; Hua XH; Cox S
Mol Cell Biochem; 2010 Jan; 333(1-2):159-67. PubMed ID: 19629644
[TBL] [Abstract][Full Text] [Related]
69. Exploring the binding of inhibitors derived from tetrabromobenzimidazole to the CK2 protein using a QM/MM-PB/SA approach.
Retegan M; Milet A; Jamet H
J Chem Inf Model; 2009 Apr; 49(4):963-71. PubMed ID: 19354274
[TBL] [Abstract][Full Text] [Related]
70. The dark side of protein kinase CK2 inhibition.
Cozza G; Meggio F; Moro S
Curr Med Chem; 2011; 18(19):2867-84. PubMed ID: 21651492
[TBL] [Abstract][Full Text] [Related]
71. The ER-membrane-resident Hsp40 ERj1 is a novel substrate for protein kinase CK2.
Götz C; Müller A; Montenarh M; Zimmermann R; Dudek J
Biochem Biophys Res Commun; 2009 Oct; 388(4):637-42. PubMed ID: 19653999
[TBL] [Abstract][Full Text] [Related]
72. Extracellular protein kinase CK2 is a novel associating protein of neuropilin-1.
Shintani Y; Takashima S; Kato H; Komamura K; Kitakaze M
Biochem Biophys Res Commun; 2009 Aug; 385(4):618-23. PubMed ID: 19486891
[TBL] [Abstract][Full Text] [Related]
73. Protein kinase CK2: a catalyst for biology, medicine and structural biochemistry.
Ahmed K; Issinger OG; Niefind K
Mol Cell Biochem; 2011 Oct; 356(1-2):1-3. PubMed ID: 21761205
[No Abstract] [Full Text] [Related]
74. Protein kinase CK2 accumulation in "oncophilic" cells: causes and effects.
Ruzzene M; Tosoni K; Zanin S; Cesaro L; Pinna LA
Mol Cell Biochem; 2011 Oct; 356(1-2):5-10. PubMed ID: 21735095
[TBL] [Abstract][Full Text] [Related]
75. Pharmacophore identification and validation study of CK2 inhibitors using CoMFA/CoMSIA.
Morshed MN; Muddassar M; Pasha FA; Cho SJ
Chem Biol Drug Des; 2009 Aug; 74(2):148-58. PubMed ID: 19563463
[TBL] [Abstract][Full Text] [Related]
76. Proteomics perturbations promoted by the protein kinase CK2 inhibitor quinalizarin.
Franchin C; Salvi M; Arrigoni G; Pinna LA
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1676-86. PubMed ID: 25882195
[TBL] [Abstract][Full Text] [Related]
77. Phosphorylation of the HuR ligand APRIL by casein kinase 2 regulates CD83 expression.
Chemnitz J; Pieper D; Grüttner C; Hauber J
Eur J Immunol; 2009 Jan; 39(1):267-79. PubMed ID: 19130553
[TBL] [Abstract][Full Text] [Related]
78. Protein Kinase CK2, a Potential Therapeutic Target in Carcinoma Management.
Lian H; Su M; Zhu Y; Zhou Y; Soomro SH; Fu H
Asian Pac J Cancer Prev; 2019 Jan; 20(1):23-32. PubMed ID: 30677865
[TBL] [Abstract][Full Text] [Related]
79. Emergence of protein kinase CK2 as a key target in cancer therapy.
Trembley JH; Chen Z; Unger G; Slaton J; Kren BT; Van Waes C; Ahmed K
Biofactors; 2010; 36(3):187-95. PubMed ID: 20533398
[TBL] [Abstract][Full Text] [Related]
80. Mass spectrometry analysis of a protein kinase CK2beta subunit interactome isolated from mouse brain by affinity chromatography.
Arrigoni G; Pagano MA; Sarno S; Cesaro L; James P; Pinna LA
J Proteome Res; 2008 Mar; 7(3):990-1000. PubMed ID: 18220339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
